Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects with a Recent Acute Coronary Syndrome + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific-Site (version 1.0, dated 17-Dec-08).

Trial Profile

Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects with a Recent Acute Coronary Syndrome + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific-Site (version 1.0, dated 17-Dec-08).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs Apixaban (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms APPRAISE-2
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Sep 2015 According to Bristol-Myers Squib media release, company has terminated the trial early due to a higher rate of bleeding with apixaban compared to placebo.
    • 18 Aug 2015 Results published in the Journal of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top